Karin Jooss
29Patents
9h-index
39Co-inventors
75Inventor score
Filing activity: Jun 3, 2003 → Jan 4, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8287856B2 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | Human Necessities | 48 | Active |
| US8580247B2 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | Human Necessities | 31 | Active |
| US7498024B2 | Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site | Chemistry; Metallurgy | 21 | Expired |
| US7186699B2 | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes | Chemistry; Metallurgy | 19 | Expired |
| US7709224B2 | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site | Chemistry; Metallurgy | 16 | Expired |
| US7485291B2 | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof | Chemistry; Metallurgy | 14 | Expired |
| US7919079B2 | Cancer immunotherapy compositions and methods of use | Human Necessities | 13 | Active |
| US7714119B2 | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same | Chemistry; Metallurgy | 10 | Expired |
| US7662623B2 | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site | Chemistry; Metallurgy | 9 | Active |
| US8840881B2 | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer | Human Necessities | 6 | Active |
| US8425897B2 | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use | Human Necessities | 5 | Active |
| US9066898B2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | Chemistry; Metallurgy | 4 | Active |
| US7632509B2 | Methods to express recombinant proteins from lentiviral vectors | Chemistry; Metallurgy | 3 | Active |
| US9468672B2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | Chemistry; Metallurgy | 2 | Active |
| US7939271B2 | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer | Physics | 2 | Active |
| US7901902B2 | Methods and compositions for identifying a cellular immune response against prostate cancer | Human Necessities | 2 | Active |
| US10660953B2 | Anti-PD-1 antibodies and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US11110158B2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | Chemistry; Metallurgy | 1 | Active |
| US12098383B2 | Modified adenoviruses | Chemistry; Metallurgy | 0 | Active |
| US11058753B2 | Cancer vaccines | Chemistry; Metallurgy | 0 | Active |
| US11591619B2 | Modified adenoviruses | Chemistry; Metallurgy | 0 | Active |
| US11510973B2 | Alphavirus antigen vectors | Chemistry; Metallurgy | 0 | Active |
| US12109257B2 | Alphavirus neoantigen vectors | Chemistry; Metallurgy | 0 | Active |
| US10251944B2 | Cancer vaccines | Chemistry; Metallurgy | 0 | Active |
| US11504421B2 | Alphavirus neoantigen vectors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.